Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
Galactoxylomannan (GalXM) is a complex polysaccharide produced by the human pathogenic fungus Cryptococcus neoformans that mediates profound immunological derangements in murine models. GalXM is essentially non-immunogenic and produces immune paralysis in mice. Previous studies have attempted to enhance immunogenicity by conjugating GalXM to a protein carrier, but only transient antibody responses were elicited. Here we report the generation of two GalXM conjugates with bovine serum albumin (BSA) and protective antigen (PA) of Bacillus anthracis, respectively, using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) as the cyanylating reagent. Both conjugates induced potent and sustained antibody responses as detected by both cross antigen-based and CovaLink direct ELISAs. We confirmed the specificity of the response to GalXM by inhibition ELISA and immunofluorescence. The isotype composition analysis revealed that IgG and IgM were abundant in the immune sera against GalXM, consistent with the induction of a T cell-dependent response. IgG1 was the predominant IgG subclass against GalXM, while immunization with Quil A as adjuvant elicited a significantly higher production of IgG2a than with Freund's adjuvant. Immune sera were not opsonic for C. neoformans and there was no survival difference between immune and non-immune mice challenged with C. neoformans. These results demonstrated the effectiveness of the GalXM-protein conjugate to induce robust immune responses although no evidence was obtained that such responses contributed to host defense.
Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, USA.
Siu-Kei
SK
Chow
Arturo
A
Casadevall
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000908:Antibodies, Fungal / Q000097:blood; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology*; D001427:Bacterial Toxins / Q000737:chemistry / Q000276:immunology*; D003453:Cryptococcosis / Q000276:immunology / Q000517:prevention & control*; D003455:Cryptococcus neoformans / Q000737:chemistry / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D005657:Fungal Vaccines / Q000737:chemistry / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D009895:Opsonin Proteins / Q000276:immunology; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000302:isolation & purification; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000276:immunology*; D016019:Survival Analysis; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology
D000276:Adjuvants, Immunologic; D000908:Antibodies, Fungal; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D005657:Fungal Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009895:Opsonin Proteins; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate; C030325:anthrax toxin; D012710:Serum Albumin, Bovine; C043689:galactoxylomannan
Carbohydr Res. 1998 Jan;306(1-2):315-30
9691456
J Immunol. 1990 Dec 1;145(11):3594-600
2246504
Vaccine. 2009 Jan 1;27(1):45-50
18977261
Biochim Biophys Acta. 1966 Apr 25;117(2):305-13
5961297
Infect Immun. 1992 Mar;60(3):1084-8
1541523
Infect Immun. 1994 May;62(5):1507-12
8168912
Cell Microbiol. 2008 Jun;10(6):1274-85
18284419
Vaccine. 2009 Jun 2;27(27):3513-8
19464529
J Infect Dis. 1996 May;173(5):1222-31
8627076
J Immunol. 1967 May;98(5):914-22
5337670
Biol Proced Online. 2004;6:10-15
15103395
Diagn Clin Immunol. 1988;5(6):344-8
3064947
J Exp Med. 1997 Feb 17;185(4):685-94
9034147
J Immunol. 2001 Jan 15;166(2):1087-96
11145689
J Exp Med. 1993 Apr 1;177(4):1105-16
8459205
Eur J Immunol. 1995 Mar;25(3):823-9
7705414
Nature. 1990 Apr 26;344(6269):873-5
2184369
Vaccine. 1996 Feb;14(3):190-8
8920699
J Infect Dis. 1998 Oct;178(4):1213-6
9806064
Infect Immun. 1987 Mar;55(3):742-8
3546139
Cell Immunol. 1971 Oct;2(5):411-24
4941003
PLoS One. 2010 Sep 14;5(9):e12720
20856869
Carbohydr Res. 2009 May 12;344(7):915-20
19345342
Infect Immun. 1987 Aug;55(8):1895-9
2440810
Eukaryot Cell. 2009 Jan;8(1):96-103
18952901
Infect Immun. 1991 Oct;59(10):3700-7
1716613
J Biol Chem. 2006 Jan 27;281(4):1868-75
16278213
J Immunol. 2009 May 15;182(10):6003-10
19414751
Eukaryot Cell. 2004 Dec;3(6):1601-8
15590833
Eukaryot Cell. 2010 Jul;9(7):1018-28
20061411
J Exp Med. 1975 Nov 1;142(5):1263-82
1194852
Mol Cell Biol. 1994 Jul;14(7):4912-9
8007987
Vaccine. 1996 Jun;14(9):841-4
8843625
J Exp Med. 1995 Jan 1;181(1):405-9
7807020
J Exp Med. 1971 Jul 1;134(1):103-19
4104294
Vaccine. 2009 Mar 13;27(12):1787-96
19208455
J Chromatogr A. 2008 Dec 12;1213(2):169-75
18992885
Eukaryot Cell. 2003 Aug;2(4):655-63
12912884
J Clin Microbiol. 1979 Oct;10(4):459-63
43335
Infect Immun. 1994 Mar;62(3):1079-88
8112842
Rev Infect Dis. 1984 Sep-Oct;6(5):619-24
6209768
Infect Immun. 2004 Jul;72(7):4271-4
15213172
Fungal Genet Biol. 2009 Jun-Jul;46(6-7):496-505
19285564
Pediatr Infect Dis J. 2002 Sep;21(9):810-5
12352800
J Immunol. 2009 Sep 15;183(6):3885-94
19684080
Cell Microbiol. 2006 Feb;8(2):267-75
16441437
J Infect Dis. 1992 Jun;165(6):1086-93
1583327
J Immunol Methods. 1992 Sep 18;154(1):27-35
1401941
Nature. 1981 Jan 29;289(5796):409-11
7464909
Infect Immun. 2007 Jun;75(6):2729-39
17371865
FEMS Yeast Res. 2006 Jun;6(4):513-24
16696647